Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDYMION long-term extension study of TAK-935 in rare epileptic encephalopathies
MOH_2019-04-23_007096Phase 2Not yet recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Ovid Therapeutics. Primary endpoint: Long-term safety and tolerability of TAK-935. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
soticlestat
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on MOH_2019-04-23_007096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-23_007096.